Market news

– ARV-6723 is an investigational, oral PROTAC designed to degrade HPK1, a negative regulator of immune activation, in advanced solid tumors – NEW HAVEN, Conn., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that the first participant has been dosed in its Phase 1/2 clinical trial of ARV-6723, an investigational, oral PROteolysis TArgeting Chimera (PROTAC)

Arvinas (NASDAQ:ARVN) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time access to earnings

On August 4, Arvinas Inc. (NASDAQ:ARVN) reported second-quarter 2026 financial results and a corporate update that doubled as one of the more consequential updates in the company’s history. The clinical-stage biotech disclosed the first-ever FDA approval of a PROTAC, a heterobifunctional protein degrader, alongside a licensing deal that hands off commercial duties to another drugmaker. […]

Detailed price information for Pfizer Inc (PFE-N) from The Globe and Mail including charting and trades.

Detailed price information for Arvinas Inc (ARVN-Q) from The Globe and Mail including charting and trades.

Arvinas (ARVN) has an average rating of overweight and mean price target of $13.93, according to ana

Detailed price information for Arvinas Inc (ARVN-Q) from The Globe and Mail including charting and trades.

Detailed price information for Arvinas Inc (ARVN-Q) from The Globe and Mail including charting and trades.

Detailed price information for Exagen Inc (XGN-Q) from The Globe and Mail including charting and trades.

Detailed price information for Arvinas Inc (ARVN-Q) from The Globe and Mail including charting and trades.

Moby summary of Arvinas, Inc.'s Q2 2026 earnings call

Arvinas (ARVN) has an average rating of overweight and mean price target of $15.08, according to ana

Arvinas (NASDAQ:ARVN) said it is concentrating resources on its early-stage oncology and neurology pipeline after reaching several strategic milestones in the first half of 2026, including FDA approval of VEPPANU, the first approved PROTAC degrader, and an out-licensing agreement for the product wit

Arvinas (NASDAQ:ARVN) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time access to earnings

Arvinas (ARVN) delivered earnings and revenue surprises of +1,175.00% and +562.56%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Detailed price information for Pfizer Inc (PFE-N) from The Globe and Mail including charting and trades.

– Secured the first-ever regulatory approval of a PROTAC (a type of heterobifunctional protein degrader), VEPPANU, and successfully completed out-licensing to Rigel Pharmaceuticals – – Anticipates sharing clinical data from three Phase 1 programs - ARV-393, ARV-102 and ARV-027 - over the next 12 months – – Presented promising preclinical data for HPK1 degrader program (ARV-6723) demonstrating the potential to overcome immune checkpoint inhibitor resistance in solid tumors – – Company to host con

NEW HAVEN, Conn., July 28, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review second quarter 2026...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

NEW HAVEN, Conn., July 28, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review second quarter 2026 financial results and provide a corporate update during a live webcast on Tuesday, August 4, 2026 at 8:00 a.m. ET. The webcast can be accessed under “Events and Presentations” on the investor page of the Arvinas website. A replay of the webcast will be availabl

Kymera Therapeutics advances KT-621 enrollment ahead of schedule, bringing pivotal atopic dermatitis data closer as it expands its protein degrader pipeline.